SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (6191)12/28/1998 1:26:00 PM
From: scaram(o)uche  Read Replies (1) of 9719
 
BJ:

Neither was Hoechst. After signing the TKTX deal, they needed to license technology from CEGE. CEGE is considered as a full partner in the collaboration, moving forward........

patent.womplex.ibm.com

Priority date, 11/6/89.......

What is claimed is:
1. A method for production of a mammalian gene product in cell culture, comprising culturing a
mammalian continuous cell line which expresses an exogenous mammalian target gene controlled by a
nucleotide regulatory sequence heterologous to said mammalian target gene, and recovering the
mammalian target gene product from said cell culture, in which said mammalian continuous cell line
was prepared by:

(a) integrating, via targeted homologous recombination, said nucleotide heterologous to said
mammalian target gene said target gene contained in a yeast artificial chromosome maintained
in a yeast host cell, so that said integrated nucleotide regulatory sequence is operably
associated with said mammalian target gene contained in said yeast artificial chromosome to
form a recombined mammalian target gene; in said yeast host cell and
(b) transferring said recombined mammalian target gene to a mammalian continuous cell line
capable of expressing said target gene product under the control of said integrated nucleotide
regulatory sequence so that the mammalian target gene product is expressed by the
mammalian continuous cell line in culture.
***********************************

BTW..... I told Gordon Binder about technologies that he would want at CEGE just after the TKTX/Hoechst deal first made a stink. AMGN decided to pass on the suggestion to finance a collaborative effort between ARIA and CEGE. Hoechst subsequently signed deals with both of them.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News